Loading patent…
AssigneeSynaptic Pharmaceutical Corporation
InventorsCharles Gluchowski, Carlos C. Forray, George Chiu, Theresa A. Branchek, John M. Wetzel, Paul R. Hartig
Estimating the term…
A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human α1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human α1A adrenergic receptor, a human α1B adrenergic receptor, and a human histamine H1 receptor, and, binds to a human α2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such α1C adrenergic receptor. Compounds meeting these criteria are provided.
A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an amount of a compound effective to treat benign prostatic hyperplasia, which compound:
A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an amount of a compound effective to treat benign prostatic hyperplasia, which compound:
A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an amount of a compound effective to treat benign prostatic hyperplasia, which compound:
A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an amount of a compound effective to treat benign prostatic hyperplasia, which compound:
Dependencies are inferred from the claim text.